A Multi-centre, Open-label, Non-controlled Trial on Safety and Efficacy of N8 in Prevention and Treatment of Bleeds in Previously Treated Subjects With Haemophilia A. Sub-trial: Safety and Efficacy of N8 in Prevention and Treatment of Bleeding During Surgical Procedures in Subjects With Haemophilia A
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Turoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Registrational
- Acronyms guardian-1
- Sponsors Novo Nordisk
- 02 Dec 2013 New trial record